Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | EVP Research & Development | October 06, 2026 | October 06, 2026 |
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | Director | June 18, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date October 06, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 153,902 |
Ending reported balance
After 2026-10-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-06 · Exercise / conversion · Acquired 3,500 · Balance 157,402 Row 2 · 2026-10-06 · Sale · Disposed 3,500 · Balance 153,902 |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2028-02-27 | Direct | 19,886 |
Reported balance
After 2026-10-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-06 · Exercise / conversion · Disposed 3,500 · Balance 19,886 |
ROCKET PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,862 |
Reported balance
After 2026-06-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 22,862 · Balance 52,862 F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2036-06-18 | Direct | 64,860 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 64,860 · Balance 64,860 F2: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027.
F2: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 14, 2024 Filed Mar 18, 2024 22:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 23,103 | $0.00 Strike: $63.75 | $0.00 |
DisclosureSEC source: 0001127602-24-010516 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,103 Underlying: Common Stock · 23,103 shares Expires 2034-03-14 F2 · kind: This option shall vest and become exercisable in equal monthly installments over 4 years commencing on April 15, 2024, with the final installment vesting on March 14, 2034. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 22:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (Right to Buy) · Derivative | 1,541 | $0.00 Strike: $63.75 | $0.00 |
DisclosureSEC source: 0001127602-24-010516 · form4.xml · derivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,541 Underlying: Common Stock · 1,541 shares Expires 2034-03-13 F2 · kind: This option shall vest and become exercisable in equal monthly installments over 4 years commencing on April 15, 2024, with the final installment vesting on March 14, 2034. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 22:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 21,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-010516 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,567 F1 · kind: Award comprised of Restricted Stock Units that will vest over 3-years, with 40% vesting on the 1-year anniversary of the date of grant, an additional 40% vesting on the 2-year anniversary of the date of grant, and the remaining 20% vesting on the 3-year anniversary of the date of grant. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 21:24 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 8,109 | $66.88 | $542,329.92 |
DisclosureSEC source: 0001127602-24-009016 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,234 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units and does not represent a sale by the reporting person. Read SEC document |
| March 05, 2024 Filed Mar 5, 2024 21:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 28,604 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001127602-24-008501 · form4.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,605 Underlying: Common Stock · 28,604 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 26, 2023. Read SEC document |
| March 05, 2024 Filed Mar 5, 2024 21:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 28,604 | $67.56 | $1,932,486.24 |
DisclosureSEC source: 0001127602-24-008501 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,973 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 26, 2023. Read SEC document |
| March 05, 2024 Filed Mar 5, 2024 21:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 28,604 | $6.67 | $190,788.68 |
DisclosureSEC source: 0001127602-24-008501 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,577 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 26, 2023. Read SEC document |
| March 05, 2024 Filed Mar 5, 2024 21:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,000 | $67.53 | $270,120.00 |
DisclosureSEC source: 0001127602-24-008501 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,973 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 26, 2023. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 21:24 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 9,630 | $67.68 | $651,758.40 |
DisclosureSEC source: 0001127602-24-009016 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,343 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units and does not represent a sale by the reporting person. Read SEC document |
| February 06, 2024 Filed Feb 6, 2024 21:43 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 28,605 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001127602-24-003582 · form4.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,209 Underlying: Common Stock · 28,605 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 26, 2023. Read SEC document |
| February 06, 2024 Filed Feb 6, 2024 21:43 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,000 | $79.28 | $317,120.00 |
DisclosureSEC source: 0001127602-24-003582 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,973 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 26, 2023. Read SEC document |
| February 06, 2024 Filed Feb 6, 2024 21:43 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 28,605 | $79.30 | $2,268,376.50 |
DisclosureSEC source: 0001127602-24-003582 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,973 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 26, 2023. Read SEC document |
| February 06, 2024 Filed Feb 6, 2024 21:43 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 28,605 | $6.67 | $190,795.35 |
DisclosureSEC source: 0001127602-24-003582 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 26, 2023. Read SEC document |
| January 04, 2024 Filed Jan 4, 2024 21:36 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 11,678 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-24-000835 · form4.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,678 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 26, 2023. Read SEC document |
| January 04, 2024 Filed Jan 4, 2024 21:36 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,000 | $86.99 | $347,960.00 |
DisclosureSEC source: 0001127602-24-000835 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,973 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 26, 2023. Read SEC document |
| January 04, 2024 Filed Jan 4, 2024 21:36 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 11,678 | $86.98 | $1,015,752.44 |
DisclosureSEC source: 0001127602-24-000835 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,973 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 26, 2023. Read SEC document |
| January 04, 2024 Filed Jan 4, 2024 21:36 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 11,678 | $7.96 | $92,956.88 |
DisclosureSEC source: 0001127602-24-000835 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 26, 2023. Read SEC document |
| November 09, 2023 Filed Nov 9, 2023 21:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,500 | $35.40 | $88,500.00 |
DisclosureSEC source: 0001127602-23-027106 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,664 Read SEC document |
| October 12, 2023 Filed Oct 12, 2023 22:39 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,500 | $35.89 | $89,725.00 |
DisclosureSEC source: 0001127602-23-025821 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,164 Read SEC document |
| September 14, 2023 Filed Sep 14, 2023 20:09 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,500 | $34.86 | $87,150.00 |
DisclosureSEC source: 0001127602-23-024158 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 155,664 Read SEC document |
| August 10, 2023 Filed Aug 10, 2023 20:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,500 | $31.70 | $79,250.00 |
DisclosureSEC source: 0001127602-23-022288 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,164 Read SEC document |
| July 13, 2023 Filed Jul 13, 2023 20:09 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,500 | $35.37 | $88,425.00 |
DisclosureSEC source: 0001127602-23-020650 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,664 Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 23:47 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 25,850 | $0.00 Strike: $21.56 | $0.00 |
DisclosureSEC source: 0001140361-23-031530 · form4.xml · derivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,850 Underlying: Common Stock · 25,850 shares Expires 2033-06-22 F1 · derivative.exercise_date: This option represents a right to purchase a total of 25,850 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 22, 2024. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 20:31 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,500 | $38.07 | $95,175.00 |
DisclosureSEC source: 0001127602-23-018297 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,164 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| May 11, 2023 Filed May 11, 2023 21:26 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,787 | $39.50 | $70,586.50 |
DisclosureSEC source: 0001127602-23-015291 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,396 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| May 03, 2023 Filed May 3, 2023 20:46 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-23-014289 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,322 Underlying: Common Stock · 7,000 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 20, 2022. Read SEC document |
| May 03, 2023 Filed May 3, 2023 20:46 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 7,000 | $40.00 | $280,000.00 |
DisclosureSEC source: 0001127602-23-014289 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,183 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 20, 2022. Read SEC document |
| May 03, 2023 Filed May 3, 2023 20:46 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 7,000 | $7.96 | $55,720.00 |
DisclosureSEC source: 0001127602-23-014289 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 174,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 20, 2022. Read SEC document |
| April 13, 2023 Filed Apr 13, 2023 20:49 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,000 | $34.21 | $136,840.00 |
DisclosureSEC source: 0001127602-23-012887 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,183 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| March 09, 2023 Filed Mar 9, 2023 22:09 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,000 | $39.10 | $156,400.00 |
DisclosureSEC source: 0001127602-23-009590 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,183 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| March 06, 2023 Filed Mar 7, 2023 21:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 77,445 | $0.00 Strike: $39.13 | $0.00 |
DisclosureSEC source: 0001127602-23-009288 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,445 Underlying: Common Stock · 77,445 shares Expires 2033-03-06 F2 · kind: This option shall vest and become exercisable in equal monthly installments over 4 years commencing on April 6, 2023, with the final installment vesting on April 6, 2027. Read SEC document |
| March 06, 2023 Filed Mar 7, 2023 21:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (Right to Buy) · Derivative | 2,555 | $0.00 Strike: $39.13 | $0.00 |
DisclosureSEC source: 0001127602-23-009288 · form4.xml · derivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,555 Underlying: Common Stock · 2,555 shares Expires 2033-03-06 F2 · kind: This option shall vest and become exercisable in equal monthly installments over 4 years commencing on April 6, 2023, with the final installment vesting on April 6, 2027. Read SEC document |
| March 06, 2023 Filed Mar 7, 2023 21:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-009288 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,183 F1 · kind: Award comprised of Restricted Stock Units that will vest over 3-years, with 40% vesting on the 1-year anniversary of the date of grant, an additional 40% vesting on the 2-year anniversary of the date of grant, and the remaining 20% vesting on the 3-year anniversary of the date of grant. Read SEC document |
| March 06, 2023 Filed Mar 7, 2023 21:07 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 4,958 | $39.13 | $194,006.54 |
DisclosureSEC source: 0001127602-23-009271 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,183 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on March 6, 2023 and does not represent a sale by the reporting person. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 23:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 10,785 | $39.60 | $427,086.00 |
DisclosureSEC source: 0001127602-23-008868 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,141 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on March 2, 2023 and does not represent a sale by the reporting person. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 22:49 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 1,513 | $44.13 | $66,768.69 |
DisclosureSEC source: 0001127602-23-005920 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,926 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on February 16, 2023 and does not represent a sale by the reporting person. Read SEC document |
| February 10, 2023 Filed Feb 10, 2023 21:45 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GiftCommon Stock | 150 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004492 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,439 F1 · kind: Bona fide gift. Read SEC document |
| February 09, 2023 Filed Feb 9, 2023 22:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,000 | $43.73 | $174,920.00 |
DisclosureSEC source: 0001127602-23-004260 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,589 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| February 09, 2023 Filed Feb 9, 2023 21:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-23-004235 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,322 Underlying: Common Stock · 7,000 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 20, 2022. Read SEC document |
| February 09, 2023 Filed Feb 9, 2023 21:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 7,000 | $43.74 | $306,180.00 |
DisclosureSEC source: 0001127602-23-004235 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,589 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 20, 2022. Read SEC document |
| February 09, 2023 Filed Feb 9, 2023 21:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 7,000 | $7.96 | $55,720.00 |
DisclosureSEC source: 0001127602-23-004235 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 20, 2022. Read SEC document |
| January 12, 2023 Filed Jan 12, 2023 21:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,000 | $40.47 | $161,880.00 |
DisclosureSEC source: 0001127602-23-001332 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,589 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| December 08, 2022 Filed Dec 8, 2022 21:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,000 | $36.28 | $145,120.00 |
DisclosureSEC source: 0001127602-22-027076 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,589 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| November 10, 2022 Filed Nov 10, 2022 23:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,000 | $38.04 | $152,160.00 |
DisclosureSEC source: 0001127602-22-025325 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,346 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| October 13, 2022 Filed Oct 13, 2022 22:36 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 21,513 | $0.00 Strike: $9.65 | $0.00 |
DisclosureSEC source: 0001127602-22-023927 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,513 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| October 13, 2022 Filed Oct 13, 2022 22:36 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 21,513 | $47.28 | $1,017,134.64 |
DisclosureSEC source: 0001127602-22-023927 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,346 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| October 13, 2022 Filed Oct 13, 2022 22:36 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 21,513 | $9.65 | $207,600.45 |
DisclosureSEC source: 0001127602-22-023927 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 20:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 21,500 | $0.00 Strike: $9.65 | $0.00 |
DisclosureSEC source: 0001127602-22-022243 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,513 Underlying: Common Stock · 21,500 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 20:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 21,500 | $51.88 | $1,115,420.00 |
DisclosureSEC source: 0001127602-22-022243 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,346 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 20:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 21,500 | $9.65 | $207,475.00 |
DisclosureSEC source: 0001127602-22-022243 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.